ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.45% | -15.52% | 0.58% | 0.58% | -6.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.45% | -15.52% | 0.58% | 0.58% | -6.15% |
| Cost of Revenue | 28.19% | 107.61% | -6.58% | -6.58% | -9.40% |
| Gross Profit | -5.26% | -105.57% | 6.62% | 6.62% | -2.79% |
| SG&A Expenses | -10.11% | -6.92% | -25.66% | -25.66% | -7.24% |
| Depreciation & Amortization | -74.28% | -0.70% | -8.04% | -8.04% | -9.57% |
| Other Operating Expenses | -95.43% | -83.33% | -65.92% | -65.92% | 51.04% |
| Total Operating Expenses | -29.74% | -18.04% | -15.28% | -15.28% | 1.09% |
| Operating Income | 31.07% | 18.13% | 15.68% | 15.68% | -1.34% |
| Income Before Tax | 20.18% | 8.80% | 9.39% | 9.39% | -10.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.18% | 8.40% | 9.07% | 9.07% | -11.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.18% | 8.40% | 9.07% | 9.07% | -11.42% |
| EBIT | 31.07% | 18.13% | 15.68% | 15.68% | -1.34% |
| EBITDA | 20.14% | 22.40% | 17.10% | 17.10% | -4.54% |
| EPS Basic | 25.88% | 15.08% | 14.72% | 14.72% | -6.30% |
| Normalized Basic EPS | 25.86% | 15.60% | 15.11% | 15.11% | -5.45% |
| EPS Diluted | 22.37% | 8.79% | 15.23% | 15.23% | 0.00% |
| Normalized Diluted EPS | 25.86% | 15.60% | 15.11% | 15.11% | -5.45% |
| Average Basic Shares Outstanding | 7.76% | 7.97% | 6.73% | 6.73% | 4.95% |
| Average Diluted Shares Outstanding | 7.76% | 7.97% | 6.73% | 6.73% | 4.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |